NCT Number: NCT01899976
X-MAS Biliary Study With Covered Biliary Stent
The purpose of this study is to provide safety and efficacy data for the X-Suit NIR® Covered Biliary Metallic Stent for subjects with malignant stricture(s) in the biliary tree. The study is designed to support the regulatory requirement of a 510(k) marketing application in the United States.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Hôpital Erasme Brussels (ULB), Brussels, Belgium
About this study
This is a non-randomized, multi-center, prospective, single arm clinical study of the X-Suit NIR® Covered Biliary Metallic Stent for the palliation of malignant strictures in the biliary tree via endoscopic approach.
Adult males and females (≥ 18 years old), with clinical symptoms of biliary obstruction and inoperable extrahepatic biliary obstruction by any malignant process.
The expected duration of this study is approximately 18 months from the time of first subject enrollment to the time of the last subject's 6-month post stent implantation follow-up visit.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age 18 or older.
- Clinical symptoms of biliary obstruction.
- Presence of inoperable extrahepatic distal biliary obstruction by any malignant process (the subject not being a surgical candidate based on the finding of a pancreatic mass >2.0cm or a severe medical illness).
- Subject is willing and able to comply with the study procedures and provide written informed consent to participate in the study.
- Insured by Social Security (applicable to subjects screened in France).
Exclusion criteria
- 1. Participation in an Investigational Study within 90 days prior to date of subject consent.
- Perforation of any duct within the biliary tree. 3. Presence of more than one previously implanted plastic stent. 4. Previous plastic stent implantation less than 2 weeks prior to current procedure.
- Presence of a metal biliary stent. 6. Presence of any esophageal or duodenal stent. 7. Previous Bilroth II or Roux-en-Y gastric resection, a significant duodenal obstruction or any other altered anatomy which could prevent access to ampulla.
- Subjects for whom endoscopic procedures are contraindicated. 9. Subjects with known sensitivity to any components of the stent or delivery system.
- Subjects with active hepatitis or other hepatic diseases that may cause jaundice.
- Subjects with a WHO performance score of 4 - Bedbound (completely disabled, cannot carry on any self-care, totally confined to bed or chair).
- Subjects known to be pregnant.
Cholangiographic exclusion criterion:
- Strictures that cannot be passed by the guide wire or the delivery system.
Treatment and study plan
Primary outcomes
-
Maintenance of a total serum bilirubin level ≤ 3.0 mg/dL or a reduction of >30% if baseline value was greater than 3.0 mg/dL
Time frame: 6 months follow up or prior to death, whichever comes first
Maintenance of a total serum bilirubin level ≤ 3.0 mg/dL or a reduction of >30% if baseline value was greater than 3.0 mg/dL- outcome
Secondary outcomes
-
total number of adverse events
Time frame: 6 months
total number of adverse events (anticipated and unanticipated)
Sponsors and collaborators
Lead sponsor
Medinol Ltd.
Industry
Registry information
Official study title
A Non-Randomized, Multi-Center, Prospective, Single Arm Clinical Study of the X-SUIT NIR® Covered Biliary Metallic Stent for Palliation of Malignant Strictures in the Biliary Tree Via Endoscopic Approach
Important dates
- Study start
- 2013
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Jul 16, 2013
- Registry last updated
- Apr 13, 2022
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
NCT05512377
Biliary Tract Cancer, Biliary Tract Diseases
Mobile, Alabama, United States
View Trial DetailsPredicting Disease Progression and/or Recurrence in Cancer
NCT04776837
Biliary Tract Cancer, Biliary Tract Diseases
Boston, Massachusetts, United States
View Trial DetailsA Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients
NCT07101874
Biliary Tract Cancer, Biliary Tract Diseases
Aichi, Japan
View Trial DetailsESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT06973161
Adnexal Diseases, Biliary Tract Cancer
Spartanburg, South Carolina, United States
View Trial Details